A Phase 1, Multi-center, Randomized, Double-Blind, Placebo-controlled, Dose-escalation Safety Assessment Study of Combination Treatment With IMO-2125 and Ribavirin in Naive Hepatitis C-infected, Genotype 1 Patients.

Trial Profile

A Phase 1, Multi-center, Randomized, Double-Blind, Placebo-controlled, Dose-escalation Safety Assessment Study of Combination Treatment With IMO-2125 and Ribavirin in Naive Hepatitis C-infected, Genotype 1 Patients.

Completed
Phase of Trial: Phase I

Latest Information Update: 08 Jan 2016

At a glance

  • Drugs IMO 2125 (Primary) ; Peginterferon alfa-2a; Ribavirin
  • Indications Hepatitis C
  • Focus Adverse reactions
  • Sponsors Idera Pharmaceuticals
  • Most Recent Events

    • 03 Apr 2011 Results presented at the 46th Annual Meeting of the European Association for the Study of the Liver.
    • 11 Mar 2011 Status changed from recruiting to completed based on information reported in an Idera Pharmaceuticals media release.
    • 21 Dec 2010 Preliminary results have been announced in an Idera Pharmaceuticals media release, and are expected to be presented at a scientific meeting in 2011.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top